We narrowed to 7,217 results for: plasmid dna

#123309-AAVrg

Ready-to-use AAV Retrograde particles produced from pAAV-hSyn-GRAB_NE1h (#123309). In addition to the viral particles, you will also receive purified pAAV-hSyn-GRAB_NE1h plasmid DNA. hSyn-driven expression of GRAB-NE1h norepinephrine sensor in neurons. These AAV were produced with a retrograde serotype, which permits retrograde access to projection neurons. These AAV preparations are suitable purity for injection into animals.

Yulong Li

Feng et al Neuron. 2019 May 22;102(4):745-761.e8. d

June 22, 2020

Academic Institutions and Nonprofits only

#137156-AAV8

Ready-to-use AAV8 particles produced from pAAV-nEF-Con/Foff 2.0-iC++-EYFP (#137156). In addition to the viral particles, you will also receive purified pAAV-nEF-Con/Foff 2.0-iC++-EYFP plasmid DNA. nEF-driven, Cre-dependent expression of chloride-conducting channelrhodopsin iC++-EYFP (inhibited in presence of Flp) for optogenetic inhibition. These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth, INTRSECT 2.0 Project

Fenno et al Neuron. 2020 Jun 20. pii: S0896-6273(20)

Nov. 25, 2020

Academic Institutions and Nonprofits only

#162382-AAV5

Ready-to-use AAV5 particles produced from pGP-AAV-CAG-FLEX-jGCaMP8f-WPRE (#162382). In addition to the viral particles, you will also receive purified pGP-AAV-CAG-FLEX-jGCaMP8f-WPRE plasmid DNA. CAG-driven, Cre-dependent expression of the ultrafast calcium sensor GCaMP8f. These AAV preparations are suitable purity for injection into animals.

GENIE Project

Zhang et al Janelia Research Campus, Online Resource

Sept. 27, 2023

Academic Institutions and Nonprofits only

#137140-AAV8

Ready-to-use AAV8 particles produced from pAAV-nEF-Con/Foff 2.0-ChR2(ET/TC)-EYFP (#137140). In addition to the viral particles, you will also receive purified pAAV-nEF-Con/Foff 2.0-ChR2(ET/TC)-EYFP plasmid DNA. nEF-driven, Cre-dependent expression of ChR2(E123T/T159C)-EYFP (inhibited in presence of Flp) for optogenetic activation. These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth, INTRSECT 2.0 Project

Fenno et al Neuron. 2020 Jun 20. pii: S0896-6273(20)

May 6, 2021

Academic Institutions and Nonprofits only

#122063-AAV2

Ready-to-use AAV2 particles produced from pAAV-EF1α1.1-ChrimsonR-GFP (#122063). In addition to the viral particles, you will also receive purified pAAV-EF1α1.1-ChrimsonR-GFP plasmid DNA. EF1a-driven expression of ChrimsonR-GFP for optogenetic activation. These AAV preparations are suitable purity for injection into animals.

Edward Boyden

Klapoetke et al Nat Methods. 2014 Mar;11(3):338-46. doi:

Aug. 7, 2025

Academic Institutions and Nonprofits only

#59133-AAV1

Ready-to-use AAV1 particles produced from pOTTC589 - pAAV c-fos Nuc-eYFP (#59133). In addition to the viral particles, you will also receive purified pOTTC589 - pAAV c-fos Nuc-eYFP plasmid DNA. C-fos-driven expression of Nuc-eYFP. These AAV preparations are suitable purity for injection into animals.

Brandon Harvey

Richie et al J Neurosci Methods. 2017 Jun 1;284:1-14.

Jan. 15, 2026

Academic Institutions and Nonprofits only

#140135-PHPeB

Ready-to-use AAV PHP.eB particles produced from pAAV-EF1a-iCreV (#140135). In addition to the viral particles, you will also receive purified pAAV-EF1a-iCreV plasmid DNA. EF1a-driven, light-inducible iCreV recombinase for spatiotemporally precise optogenomic modifications. These AAV were produced with the PHPeB serotype, which permits efficient transduction of the central nervous system. These AAV preparations are suitable purity for injection into animals.

Hongkui Zeng

Yao et al Nat Methods. 2020 Mar 23. pii: 10.1038/s

Sept. 15, 2021

Academic Institutions and Nonprofits only

#106176-AAV1

Ready-to-use AAV1 particles produced from pAAV.hSynapsin.SF-iGluSnFR.S72A (#106176). In addition to the viral particles, you will also receive purified pAAV.hSynapsin.SF-iGluSnFR.S72A plasmid DNA. hSynapsin driven SF-iGluSnFR.S72A, glutamate sensor. The S72A mutant has lower affinity for glutamate. Slower on-rate and faster off-rate. Enhanced temporal resolution and spatial resolution. These AAV preparations are suitable purity for injection into animals.

Loren Looger

Marvin et al Nat Methods. 2018 Nov;15(11):936-939. do

Feb. 25, 2019

Academic Institutions and Nonprofits only

#228902-AAV8

Ready-to-use AAV8 particles produced from pAAV-CAG-DIO-HA-HCARD-P2A-mCitrine (#228902). In addition to the viral particles, you will also receive purified pAAV-CAG-DIO-HA-HCARD-P2A-mCitrine plasmid DNA. CAG-driven, Cre dependent expression of a peripherally restricted DREADD. These AAV preparations are suitable purity for injection into animals.

Bryan Roth

Kang et al Cell. 2024 Dec 26;187(26):7433-7449.e20.

Oct. 8, 2025

Academic Institutions and Nonprofits only

#113050-AAVrg

Ready-to-use AAV Retrograde particles produced from pAAV-hSyn-GRAB_DA1h (#113050). In addition to the viral particles, you will also receive purified pAAV-hSyn-GRAB_DA1h plasmid DNA. Synapsin-driven expression of GRAB-DA1h dopamine sensor in neurons. These AAV preparations are suitable purity for injection into animals.

Yulong Li

Sun et al Cell. 2018 Jul 12;174(2):481-496.e19. do

Nov. 4, 2019

Academic Institutions and Nonprofits only

#139504-AAV5

Ready-to-use AAV5 particles produced from pAAV-CAG-DIO-PPO-Venus (#139504). In addition to the viral particles, you will also receive purified pAAV-CAG-DIO-PPO-Venus plasmid DNA. CAG-driven, Cre-dependent expression of Venus-tagged parapinopsin. These AAV preparations are suitable purity for injection into animals.

Michael Bruchas

Copits et al Neuron. 2021 Jun 2;109(11):1791-1809.e11

April 10, 2024

Academic Institutions and Nonprofits only

#140137-PHPeB

Ready-to-use AAV PHP.eB particles produced from pAAV-EF1a-iFlpV (#140137). In addition to the viral particles, you will also receive purified pAAV-EF1a-iFlpV plasmid DNA. EF1a-driven, light-inducible iFlpV recombinase for spatiotemporally precise optogenomic modifications. These AAV were produced with the PHPeB serotype, which permits efficient transduction of the central nervous system. These AAV preparations are suitable purity for injection into animals.

Hongkui Zeng

Yao et al Nat Methods. 2020 Mar 23. pii: 10.1038/s

Oct. 18, 2021

Academic Institutions and Nonprofits only

#137164-AAVrg

Ready-to-use AAV Retrograde particles produced from pAAV-nEF-Con/Fon/Von eYFP (#137164). In addition to the viral particles, you will also receive purified pAAV-nEF-Con/Fon/Von eYFP plasmid DNA. nEF-driven, Cre, Flp and VCre-dependent expression of EYFP. These AAV were produced with a retrograde serotype, which permits retrograde access to projection neurons. These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth, INTRSECT 2.0 Project

Fenno et al Neuron. 2020 Jun 20. pii: S0896-6273(20)

Nov. 12, 2020

Academic Institutions and Nonprofits only

#123310-AAVrg

Ready-to-use AAV Retrograde particles produced from pAAV-hSyn-GRAB_NEmut (#123310). In addition to the viral particles, you will also receive purified pAAV-hSyn-GRAB_NEmut plasmid DNA. hSyn-driven expression of GRAB-NEmut control norepinephrine sensor (does not respond to NE). These AAV were produced with a retrograde serotype, which permits retrograde access to projection neurons. These AAV preparations are suitable purity for injection into animals.

Yulong Li

Feng et al Neuron. 2019 May 22;102(4):745-761.e8. d

July 1, 2020

Academic Institutions and Nonprofits only

#140136-PHPeB

Ready-to-use AAV PHP.eB particles produced from pAAV-EF1a-iDreV (#140136). In addition to the viral particles, you will also receive purified pAAV-EF1a-iDreV plasmid DNA. EF1a-driven, light-inducible iDreV recombinase for spatiotemporally precise optogenomic modifications. These AAV were produced with the PHPeB serotype, which permits efficient transduction of the central nervous system. These AAV preparations are suitable purity for injection into animals.

Hongkui Zeng

Yao et al Nat Methods. 2020 Mar 23. pii: 10.1038/s

Nov. 29, 2021

Academic Institutions and Nonprofits only

#84445-AAV5

Ready-to-use AAV5 particles produced from pAAV-CAG-FLEX-rc [Jaws-KGC-GFP-ER2] (#84445). In addition to the viral particles, you will also receive purified pAAV-CAG-FLEX-rc [Jaws-KGC-GFP-ER2] plasmid DNA. CAG-driven, Cre-dependent Jaws-GFP for optogenetic inhibition. These AAV preparations are suitable purity for injection into animals.

Edward Boyden

Chuong et al Nat Neurosci. 2014 Aug;17(8):1123-9. doi

Oct. 10, 2018

Academic Institutions and Nonprofits only

#107312-AAV1

Ready-to-use AAV1 particles produced from AAV-hSyn-mCherry-P2A-Cre-WPRE (#107312). In addition to the viral particles, you will also receive purified AAV-hSyn-mCherry-P2A-Cre-WPRE plasmid DNA. hSyn-driven expression of mCherry and Cre (physically separate). These AAV preparations are suitable purity for injection into animals.

Hui Yang

Zhou et al Nat Neurosci. 2018 Jan 15. pii: 10.1038/

Oct. 28, 2021

Academic Institutions and Nonprofits only

#62723-AAV1

Ready-to-use AAV1 particles produced from pAAV-Syn-FLEX-rc[ChrimsonR-tdTomato] (#62723). In addition to the viral particles, you will also receive purified pAAV-Syn-FLEX-rc[ChrimsonR-tdTomato] plasmid DNA. Cre-dependent expression of ChrimsonR-tdTomato under the control of the Synapsin promoter. These AAV preparations are suitable purity for injection into animals.

Edward Boyden

Klapoetke et al Nat Methods. 2014 Mar;11(3):338-46. doi:

Sept. 27, 2024

Academic Institutions and Nonprofits only

#83899-AAV1

Ready-to-use AAV1 particles produced from pAAV-mDlx-GCaMP6f-Fishell-2 (#83899). In addition to the viral particles, you will also receive purified pAAV-mDlx-GCaMP6f-Fishell-2 plasmid DNA. mDlx-driven expression of GCaMP6f. These AAV preparations are suitable purity for injection into animals.

Gordon Fishell

Dimidschstein et al Nat Neurosci. 2016 Oct 31. doi: 10.1038/

Nov. 13, 2020

Academic Institutions and Nonprofits only

#125712-AAV1

Ready-to-use AAV1 particles produced from pAAV-CaMKIIa(0.4)-eOPN3-mScarlet-WPRE (#125712). In addition to the viral particles, you will also receive purified pAAV-CaMKIIa(0.4)-eOPN3-mScarlet-WPRE plasmid DNA. CaMKIIa-driven expression of the optimized mosquito OPN3 rhodopsin in-frame with mScarlet. These AAV preparations are suitable purity for injection into animals.

Ofer Yizhar

Mahn et al Neuron. 2021 May 10. pii: S0896-6273(21)

June 26, 2024

Academic Institutions and Nonprofits only